CRISPR/Cas9基因组编辑技术在癌症研究中的应用

doi:10.16288/j.yczz.15-252

遗传 ›› 2016, Vol. 38 ›› Issue (1): 1-8.doi: 10.16288/j.yczz.15-252

• 综述 • 下一篇

CRISPR/Cas9基因组编辑技术在癌症研究中的应用

王大勇^{1, 2, 3}, 马宁^{1, 2, 3}, 惠洋^{1, 2, 3}, 高旭^{1, 2, 3}

1. 哈尔滨医科大学生物化学与分子生物学教研室,哈尔滨 150086;
2. 哈尔滨医科大学北方转化医学研究合作中心,哈尔滨 150086;
3. 黑龙江省医学科学院,哈尔滨 150086

收稿日期:2015-08-31 修回日期:2015-11-20 出版日期:2016-01-20 发布日期:2016-01-20
通讯作者: 高旭,博士,教授,研究方向：遗传改变模式动物的建立及复杂疾病机制研究。E-mail:gaoxu_671227@163.com E-mail:84dayong@163.com
作者简介:王大勇,博士,专业方向：遗传改变模式动物的建立及复杂疾病机制研究。
基金资助:
国家自然基金项目（编号：81270511, 81200827）资助

The application of CRISPR/Cas9 genome editing technology in cancer research

Dayong Wang^{1, 2, 3}, Ning Ma^{1, 2, 3}, Yang Hui^{1, 2, 3}, Xu Gao^{1, 2, 3}

1. Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin 150086, China;
2. Translational Medicine Research and Cooperation Center of Northern China, Harbin Medical University, Harbin 150086, China;
3. Heilongjiang Academy of Medical Sciences, Harbin 150086, China

Received:2015-08-31 Revised:2015-11-20 Online:2016-01-20 Published:2016-01-20
Supported by:
[Supported by the National Natural Science Foundation of China (Nos; 81270511, 81200827)]

摘要/Abstract

摘要： CRISPR/cas9基因组编辑技术因其设计简单以及操作容易,使其在基因编辑的研究中越来越受到欢迎。利用该技术,科研人员可以实现在碱基的水平对基因组进行定点修饰。CRISPR系统现已经被广泛地应用到多个物种的基因组编辑以及癌症的相关研究中。本文在最新研究进展的基础上,结合对癌症研究及基因组编辑技术的理解,对CRISPR/Cas9技术在癌症研究中的应用进行了综述。

关键词: CRISPR, CRISPR/Cas9, 基因编辑, 癌症

Abstract: The CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein-9 nuclease) genome editing technology has become more and more popular in gene editing because of its simple design and easy operation. Using the CRISPR/Cas9 system, researchers can perform site-directed genome modification at the base level. Moreover, it has been widely used in genome editing in multiple species and related cancer research. In this review, we summarize the application of the CRISPR/Cas9 system in cancer research based on the latest research progresses as well as our understanding of cancer research and genome editing techniques.

Key words: CRISPR, CRISPR/Cas9, gene editing, cancer

王大勇, 马宁, 惠洋, 高旭. CRISPR/Cas9基因组编辑技术在癌症研究中的应用[J]. 遗传, 2016, 38(1): 1-8.

Dayong Wang, Ning Ma, Yang Hui, Xu Gao. The application of CRISPR/Cas9 genome editing technology in cancer research[J]. HEREDITAS(Beijing), 2016, 38(1): 1-8.

参考文献

[1] Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol , 1987, 169(12): 5429-5433.
[2] Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science , 2014, 346(6213): 1258096.
[3] Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell , 2014, 157(6): 1262-1278.
[4] Wang HY, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell , 2013, 153(4): 910-918.
[5] Yang H, Wang HY, Shivalila CS, Cheng AW, Shi LY, Jaenisch R. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell , 2013, 154(6): 1370-1379.
[6] Zhou XQ, Xin JG, Fan NN, Zou QJ, Huang J, Ouyang Z, Zhao Y, Zhao BT, Liu ZM, Lai SS, Yi XL, Guo L, Esteban MA, Zeng YZ, Yang HQ, Lai LX. Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer. Cell Mol Life Sci , 2015, 72(6): 1175-1184.
[7] Wan HF, Feng CJ, Teng F, Yang SH, Hu BY, Niu YY, Xiang AP, Fang WZ, Ji WZ, Li W, Zhao XY, Zhou Q. One-step generation of p53 gene biallelic mutant Cynomolgus monkey via the CRISPR/Cas system. Cell Res , 2015, 25(2): 258-261.
[8] Zhao P, Zhang Z, Ke HM, Yue YR, Xue D. Oligonucleotide-based targeted gene editing in C. elegans via the CRISPR/Cas9 system. Cell Res , 2014, 24(2): 247-250.
[9] Hruscha A, Krawitz P, Rechenberg A, Heinrich V, Hecht J, Haass C, Schmid B. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development , 2013, 140(24): 4982-4987.
[10] Hwang WY, Fu YF, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JRJ, Joung JK. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol , 2013, 31(3): 227-229.
[11] Shan QW, Wang YP, Li J, Zhang Y, Chen KL, Liang Z, Zhang K, Liu JX, Xi JZJ, Qiu JL, Gao CX. Targeted genome modification of crop plants using a CRISPR-Cas system. Nat Biotechnol , 2013, 31(8): 686-688.
[12] Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature , 2015, 517(7536): 583-588.
[13] Bikard D, Jiang WY, Samai P, Hochschild A, Zhang F, Marraffini LA. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res , 2013, 41(15): 7429-7437.
[14] Liu T, Li YJ, Wang XD, Ye Q, Li H, Liang YX, She QX, Peng N. Transcriptional regulator-mediated activation of adaptation genes triggers CRISPR de novo spacer acquisition. Nucleic Acids Res , 2015, 43(2): 1044-1055.
[15] Zhou JW, Xu QB, Yao J, Yu SM, Cao SZ. CRISPR/Cas9 genome editing technique and its application in site-directed genome modification of animals. Hereditas (Beijing) , 2015, 37(10): 1011-1020. 周金伟, 徐绮嫔, 姚婧, 余树民, 曹随忠. CRISPR/Cas9基因组编辑技术及其在动物基因组定点修饰中的应用. 遗传, 2015, 37(10): 1011-1020.
[16] Kraft K, Geuer S, Will AJ, Chan WL, Paliou C, Borschiwer M, Harabula I, Wittler L, Franke M, Ibrahim DM, Kragesteen BK, Spielmann M, Mundlos S, Lupiáñez DG, Andrey G. Deletions, inversions, duplications: engineering of structural variants using CRISPR/Cas in mice. Cell Rep , 2015, 10(5): 833-839, doi:10.1016/ j.celrep. 2015.01.016.
[17] Stell A, Biserni A, Della Torre S, Rando G, Ramachandran B, Ottobrini L, Lucignani G, Maggi A, Ciana P. Cancer modeling: modern imaging applications in the generation of novel animal model systems to study cancer progression and therapy. Int J Biochem Cell Biol , 2007, 39(7-8): 1288-1296.
[18] van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell , 2002, 108(2): 135-144.
[19] Xue W, Chen SD, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai WX, Yang G, Bronson R, Crowley DG, Zhang F, Anderson DG, Sharp PA, Jacks T. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature , 2014, 514(7522): 380-384.
[20] Platt RJ, Chen SD, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng GP, Sharp PA, Zhang F. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell , 2014, 159(2): 440-455.
[21] Ji HB, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai DP, Naumov GN, Bao L, Contreras CM, Li DN, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin XH, Shapiro GI, Jänne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK. LKB1 modulates lung cancer differentiation and metastasis. Nature , 2007, 448(7155): 807-810.
[22] Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, Kanai T, Sato T. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med , 2015, 21(3): 256-262.
[23] The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature , 2012, 487(7407): 330-337.
[24] Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol , 2014, 32(9): 941-946.
[25] Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, Joshi NS, Subbaraj L, Bronson RT, Xue W, Jacks T. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature , 2014, 516(7531): 428-431.
[26] Chen SD, Sanjana NE, Zheng KJ, Shalem O, Lee K, Shi X, Scott DA, Song J, Pan JQ, Weissleder R, Lee H, Zhang F, Sharp PA. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell , 2015, 160(6): 1246-1260.
[27] Chen SD, Xue Y, Wu XB, Le C, Bhutkar A, Bell EL, Zhang F, Langer R, Sharp PA. Global microRNA depletion suppresses tumor angiogenesis. Genes Dev , 2014, 28(10): 1054-1067.
[28] Tsai AG, Lieber MR. Mechanisms of chromosomal rearrangement in the human genome. BMC Genomics , 2010, 11(Suppl.1): S1.
[29] Holland AJ, Cleveland DW. Chromoanagenesis and cancer: mechanisms and consequences of localized, complex
chromosomal rearrangements. Nat Med , 2012, 18(11): 1630-1638.
[30] Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, Lowe SW, Ventura A. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature , 2014, 516(7531): 423-427.
[31] Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature , 2007, 448(7153): 561-566.
[32] Taki T, Taniwaki M. Chromosomal translocations in cancer and their relevance for therapy. Curr Opin Oncol , 2006, 18(1): 62-68.
[33] Torres R, Martin MC, Garcia A, Cigudosa JC, Ramirez JC, Rodriguez-Perales S. Engineering human tumour- associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat Commun , 2014, 5: 3964.
[34] Wu YX, Liang D, Wang YH, Bai MZ, Tang W, Bao SM, Yan ZQ, Li DS, Li JS. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell , 2013, 13(6): 659-662.
[35] Long CZ, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science , 2014, 345(6201): 1184-1188.
[36] Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O'Connor L, Milla L, Wilcox S, Tai L, Strasser A, Herold MJ. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor- promoting mutations in vivo . Cell Rep , 2015, 10(8): 1422-1432.
[37] Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science , 2014, 343(6166): 84-87.
[38] Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science , 2014, 343(6166): 80-84.
[39] Zhou YX, Zhu SY, Cai CZ, Yuan PF, Li CM, Huang YY, Wei WS. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature , 2014, 509(7501): 487-491.
[40] Shi JW, Wang E, Milazzo JP, Wang ZH, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol , 2015, 33(6): 661-667.
[41] Malina A, Mills JR, Cencic R, Yan YF, Fraser J, Schippers LM, Paquet M, Dostie J, Pelletier J. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev , 2013, 27(23): 2602-2614.
[42] Nihongaki Y, Yamamoto S, Kawano F, Suzuki H, Sato M. CRISPR-Cas9-based photoactivatable transcription system. Chem Biol , 2015, 22(2): 169-174.
[43] Essletzbichler P, Konopka T, Santoro F, Chen D, Gapp BV, Kralovics R, Brummelkamp TR, Nijman SMB, Bürckstummer T. Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. Genome Res , 2014, 24(12): 2059-2065.
[44] Han JX, Zhang J, Chen L, Shen B, Zhou JK, Hu B, Du YN, Tate PH, Huang XX, Zhang WS. Efficient in vivo deletion of a large imprinted lncRNA by CRISPR/Cas9. RNA Biol , 2014, 11(7): 829-835.
[45] Ho TT, Zhou NJ, Huang JG, Koirala P, Xu M, Fung R, Wu FT, Mo YY. Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res , 2015, 43(3): e17.
[46] Ablain J, Durand EM, Yang S, Zhou Y, Zon LI. A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. Dev Cell , 2015, 32(6): 756-764.
[47] Swiech L, Heidenreich M, Banerjee A, Habib N, Li YQ, Trombetta J, Sur M, Zhang F. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol , 2015, 33(1): 102-106.
[48] Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell , 2013, 154(6): 1380-1389.
[49] Shen B, Zhang WS, Zhang J, Zhou JK, Wang JY, Chen L, Wang L, Hodgkins A, Iyer V, Huang XX, Skarnes WC. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods , 2014, 11(4): 399-402.
[50] Kourtidis A, Ngok SP, Pulimeno P, Feathers RW, Carpio LR, Baker TR, Carr JM, Yan IK, Borges S, Perez EA, Storz P, Copland JA, Patel T, Thompson EA, Citi S, Anastasiadis PZ. Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity. Nat Cell Biol , 2015, 17(9): 1145-1157.
[51] Bai M, Li Q, Shao YJ, Huang YH, Li DL, Ma YL. Generation of site-specific mutant mice using the CRISPR/Cas9 system. Hereditas(Beijing) , 2015, 37(10): 1029-1035. 白敏, 李崎, 邵艳姣, 黄元华, 李大力, 马燕琳. 利用CRISPR/Cas9技术构建定点突变小鼠品系. 遗传, 2015, 37(10): 1029-1035.
[52] Qu L, Li HS, Jiang YH, Dong CS. The molecular mechanism of CRISPR/Cas9 system and its application in gene therapy of human diseases. Hereditas(Beijing) , 2015, 37(10): 974-982. 璩良, 李华善, 姜运涵, 董春升. CRISPR/Cas9系统的分子机制及其在人类疾病基因治疗中的应用. 遗传, 2015, 37(10): 974-982.
[53] Yin LJ, Hu SQ, Guo F. The application of CRISPR-Cas9 gene editing technology in viral infection diseases. Hereditas(Beijing) , 2015, 37(5): 412-418. 殷利眷, 胡斯奇, 郭斐. CRISPR-Cas9基因编辑技术在病毒感染疾病治疗中的应用. 遗传, 2015, 37(5): 412-418.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

CRISPR/Cas9基因组编辑技术在癌症研究中的应用

The application of CRISPR/Cas9 genome editing technology in cancer research

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	宗媛,高彩霞. 碱基编辑系统研究进展[J]. 遗传, 2019, 41(9): 777-800.
[2]	杨新萍,于媛,许操. 重新设计与快速驯化创造新型作物[J]. 遗传, 2019, 41(9): 827-835.
[3]	张倩倩,商璇,林宛颖,徐湘民. 影响β-地中海贫血表型的遗传修饰作用[J]. 遗传, 2019, 41(8): 669-676.
[4]	张競文,续倩,李国亮. 癌症发生发展中的表观遗传学研究[J]. 遗传, 2019, 41(7): 567-581.
[5]	牛煦然,尹树明,陈曦,邵婷婷,李大力. 基因编辑技术及其在疾病治疗中的研究进展[J]. 遗传, 2019, 41(7): 582-598.
[6]	郑晓飞,黄海燕,吴强. 染色质架构蛋白CTCF调控UGT1基因簇的表达[J]. 遗传, 2019, 41(6): 509-523.
[7]	王珏, 黄娟, 许蕊. 利用CRISPR/Cas9和piggyBac实现果蝇基因组无缝编辑[J]. 遗传, 2019, 41(5): 422-429.
[8]	欧浩,李国玲,王豪强,黄广燕,蔡更元,李紫聪,吴珍芳,张献伟. MEK抑制剂PD0325901显著提高猪胎儿成纤维细胞ssODN介导的HDR效率[J]. 遗传, 2019, 41(4): 327-336.
[9]	张楷, 刘蔚, 刘小凤, 陈瑶生, 刘小红, 何祖勇. 利用CRISPR/Cas9系统构建人HPRT1基因定点突变细胞株[J]. 遗传, 2019, 41(10): 939-949.
[10]	吴志强, 米泽云. 超级增强子在肿瘤研究中的进展[J]. 遗传, 2019, 41(1): 41-51.
[11]	刘恒, 李东明, 朱兰玉, 赖乐锦, 闫婉云, 陆玉双, 韦伊, 黄月琪, 方媚, 苏元港, 杨芳, 舒伟. 利用CRISPR/Cas9敲除人源细胞系中LMNA基因的研究[J]. 遗传, 2019, 41(1): 66-75.
[12]	任云晓, 肖茹丹, 娄晓敏, 方向东. 基因编辑技术及其在基因治疗中的应用[J]. 遗传, 2019, 41(1): 18-27.
[13]	张桂珊, 杨勇, 张灵敏, 戴宪华. 机器学习方法在CRISPR/Cas9系统中的应用[J]. 遗传, 2018, 40(9): 704-723.
[14]	黄耀强,李国玲,杨化强,吴珍芳. 基因编辑猪在生物医学研究中的应用[J]. 遗传, 2018, 40(8): 632-646.
[15]	刘海龙, 谌阳, 高杨, 周玲, 韩晓松, 赵长志, 杨高娟, 陈毅龙, 杨慧, 谢胜松. 靶向miRNA前体不同类型sgRNA的丰度及特异性评估[J]. 遗传, 2018, 40(7): 561-571.